Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Elucidating pathogenic signalling mechanisms underlying SCN2A dysfunction in Autism
FY 2019-20
Summary
Autism spectrum disorder (ASD) is a diverse group of brain disorders that exhibit a range of severities between individuals. There are currently no targeted treatments for the disorder because disease origins remain poorly understood. ASD has a major genetic component with large-scale genetic sequencing studies having identified hundreds of risk genes. Studying risk genes in animal models (eg. mice) or human stem cell (hSC)-derived neurons allows us to study how specific mutations impair brain development and lead to ASD. My project will study one of the top risk genes identified to date, SCN2A, which encodes for the Nav1.2 sodium channel, which is important for neuronal communication. The current understanding of how SCN2A mutations impair brain development and lead to ASD remain poor. Studies in mouse models of Scn2a suggest neurons lacking one copy of the gene are less active and have defects in neural communication. We have new work showing reduced neural activity in hSC-derived neurons lacking SCN2A. Therefore, I will study how the loss of SCN2A affects normal neuronal function and communication and restore SCN2A to normal levels to reverse the defects previously observed. Using a combination of transcriptomic and proteomic techniques in hSC-derived neurons of individuals with SCN2A mutations, I will shed light on how SCN2A mutations lead to abnormal brain development in ASD. Furthermore, I will increase the amount of SCN2A levels in patient stem cell-derived neurons using new CRISPR-Cas9 gene editing technologies to reverse previously seen neuronal defects. My project will be one of the first comprehensive studies on SCN2A human patient-derived neurons, revealing insight into how SCN2A mutations impair brain development and can lead to ASD symptoms.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
430782
Name
Uy Jarryll
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Elucidating pathogenic signalling mechanisms underlying SCN2A dysfunction in Autism
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autism Spectrum Disorder; Bioid; Bioinfomrmatics; Crispr-Cas9; Human Ipsc-Derived Neurons; Patient-Derived Ipsc; Proteomics; Rna-Seq
Abstract
Autism spectrum disorder (ASD) is a diverse group of brain disorders that exhibit a range of severities between individuals. There are currently no targeted treatments for the disorder because disease origins remain poorly understood. ASD has a major genetic component with large-scale genetic sequencing studies having identified hundreds of risk genes. Studying risk genes in animal models (eg. mice) or human stem cell (hSC)-derived neurons allows us to study how specific mutations impair brain development and lead to ASD. My project will study one of the top risk genes identified to date, SCN2A, which encodes for the Nav1.2 sodium channel, which is important for neuronal communication. The current understanding of how SCN2A mutations impair brain development and lead to ASD remain poor. Studies in mouse models of Scn2a suggest neurons lacking one copy of the gene are less active and have defects in neural communication. We have new work showing reduced neural activity in hSC-derived neurons lacking SCN2A. Therefore, I will study how the loss of SCN2A affects normal neuronal function and communication and restore SCN2A to normal levels to reverse the defects previously observed. Using a combination of transcriptomic and proteomic techniques in hSC-derived neurons of individuals with SCN2A mutations, I will shed light on how SCN2A mutations lead to abnormal brain development in ASD. Furthermore, I will increase the amount of SCN2A levels in patient stem cell-derived neurons using new CRISPR-Cas9 gene editing technologies to reverse previously seen neuronal defects. My project will be one of the first comprehensive studies on SCN2A human patient-derived neurons, revealing insight into how SCN2A mutations impair brain development and can lead to ASD symptoms.
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Uy, Jarryll
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~